Current Environment: Production

Daniel Duncan | Education

Medical School

Yale School of Medicine

New Haven, CT

Residency

Boston Combined Residency Program (BCRP)

2015, Boston, MA

Fellowship

Pediatrics GI/Nutrition

Boston Children's Hospital

2018, Boston, MA

Daniel Duncan | Certifications

  • American Board of Pediatrics (Gastroenterology)
  • American Board of Pediatrics (General)
  • Safe Zone Trained

Daniel Duncan | Publications

  1. A prospective study of diagnostic testing and hospital charges after brief resolved unexplained event. J Pediatr Gastroenterol Nutr. 2025 Apr; 80(4):623-632. View A prospective study of diagnostic testing and hospital charges after brief resolved unexplained event. Abstract

  2. Outcomes for infants with BRUE diagnosed with oropharyngeal dysphagia or gastroesophageal reflux disease: a multicenter study from the Pediatric Health Information System Database. Eur J Pediatr. 2025 Jan 14; 184(2):134. View Outcomes for infants with BRUE diagnosed with oropharyngeal dysphagia or gastroesophageal reflux disease: a multicenter study from the Pediatric Health Information System Database. Abstract

  3. Brief Resolved Unexplained Events Symptoms Frequently Result in Inappropriate Gastrointestinal Diagnoses and Treatment. J Pediatr. 2024 Sep; 272:114128. View Brief Resolved Unexplained Events Symptoms Frequently Result in Inappropriate Gastrointestinal Diagnoses and Treatment. Abstract

  4. Breastfeeding in infants who aspirate may increase risk of pulmonary inflammation. Pediatr Pulmonol. 2024 Mar; 59(3):600-608. View Breastfeeding in infants who aspirate may increase risk of pulmonary inflammation. Abstract

  5. Pediatric Aerodigestive Medicine: Advancing Collaborative Care for Children With Oropharyngeal Dysphagia. J Pediatr Gastroenterol Nutr. 2023 10 01; 77(4):460-467. View Pediatric Aerodigestive Medicine: Advancing Collaborative Care for Children With Oropharyngeal Dysphagia. Abstract

  6. A Prospective Study of Parental Experience with Thickening Feeds for Children with Oropharyngeal Dysphagia and Gastroesophageal Reflux. J Pediatr. 2023 09; 260:113510. View A Prospective Study of Parental Experience with Thickening Feeds for Children with Oropharyngeal Dysphagia and Gastroesophageal Reflux. Abstract

  7. Gastrointestinal factors associated with risk of bronchiectasis in children. Pediatr Pulmonol. 2023 03; 58(3):899-907. View Gastrointestinal factors associated with risk of bronchiectasis in children. Abstract

  8. A Prospective Study of Brief Resolved Unexplained Events: Risk Factors for Persistent Symptoms. Hosp Pediatr. 2022 12 01; 12(12):1030-1043. View A Prospective Study of Brief Resolved Unexplained Events: Risk Factors for Persistent Symptoms. Abstract

  9. Low diagnostic yield in BRUE hospitalization. J Pediatr. 2022 05; 244:250-254. View Low diagnostic yield in BRUE hospitalization. Abstract

  10. Circulating Cell-Free DNA Yield and Circulating-Tumor DNA Quantity from Liquid Biopsies of 12?139 Cancer Patients. Clin Chem. 2021 11 01; 67(11):1554-1566. View Circulating Cell-Free DNA Yield and Circulating-Tumor DNA Quantity from Liquid Biopsies of 12?139 Cancer Patients. Abstract

  11. Evaluating the adherence to national guidelines for treatment of gastroesophageal reflux in infants. Acta Paediatr. 2022 Feb; 111(2):440-441. View Evaluating the adherence to national guidelines for treatment of gastroesophageal reflux in infants. Abstract

  12. JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology. Am J Surg Pathol. 2021 07 01; 45(7):895-904. View JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology. Abstract

  13. Acid Suppression Does Not Improve Laryngomalacia Outcomes but Treatment for Oropharyngeal Dysphagia Might Be Protective. J Pediatr. 2021 Nov; 238:42-49.e2. View Acid Suppression Does Not Improve Laryngomalacia Outcomes but Treatment for Oropharyngeal Dysphagia Might Be Protective. Abstract

  14. Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma. Oncologist. 2021 07; 26(7):e1263-e1272. View Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma. Abstract

  15. Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas. Oncologist. 2021 05; 26(5):375-382. View Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas. Abstract

  16. Overlapping Symptoms of Gastroesophageal Reflux and Aspiration Highlight the Limitations of Validated Questionnaires. J Pediatr Gastroenterol Nutr. 2021 03 01; 72(3):372-377. View Overlapping Symptoms of Gastroesophageal Reflux and Aspiration Highlight the Limitations of Validated Questionnaires. Abstract

  17. Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma. Mod Pathol. 2021 07; 34(7):1425-1433. View Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma. Abstract

  18. Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer. Oncologist. 2020 11; 25(11):943-953. View Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer. Abstract

  19. Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss. Gynecol Oncol. 2020 05; 157(2):357-366. View Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss. Abstract

  20. Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response. Oncologist. 2020 02; 25(2):e198-e202. View Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response. Abstract

  21. Clinical Aspects of Thickeners for Pediatric Gastroesophageal Reflux and Oropharyngeal Dysphagia. Curr Gastroenterol Rep. 2019 May 16; 21(7):30. View Clinical Aspects of Thickeners for Pediatric Gastroesophageal Reflux and Oropharyngeal Dysphagia. Abstract

  22. The Impact of the American Academy of Pediatrics Brief Resolved Unexplained Event Guidelines on Gastrointestinal Testing and Prescribing Practices. J Pediatr. 2019 08; 211:112-119.e4. View The Impact of the American Academy of Pediatrics Brief Resolved Unexplained Event Guidelines on Gastrointestinal Testing and Prescribing Practices. Abstract

  23. Feeding Interventions Are Associated With Improved Outcomes in Children With Laryngeal Penetration. J Pediatr Gastroenterol Nutr. 2019 02; 68(2):218-224. View Feeding Interventions Are Associated With Improved Outcomes in Children With Laryngeal Penetration. Abstract

  24. Association of Proton Pump Inhibitors With Hospitalization Risk in Children With Oropharyngeal Dysphagia. JAMA Otolaryngol Head Neck Surg. 2018 12 01; 144(12):1116-1124. View Association of Proton Pump Inhibitors With Hospitalization Risk in Children With Oropharyngeal Dysphagia. Abstract

  25. Presenting Signs and Symptoms do not Predict Aspiration Risk in Children. J Pediatr. 2018 10; 201:141-146. View Presenting Signs and Symptoms do not Predict Aspiration Risk in Children. Abstract

  26. Oropharyngeal Dysphagia Is Strongly Correlated With Apparent Life-Threatening Events. J Pediatr Gastroenterol Nutr. 2017 08; 65(2):168-172. View Oropharyngeal Dysphagia Is Strongly Correlated With Apparent Life-Threatening Events. Abstract

  27. Gastroesophageal Reflux Burden, Even in Children That Aspirate, Does Not Increase Pediatric Hospitalization. J Pediatr Gastroenterol Nutr. 2016 08; 63(2):210-7. View Gastroesophageal Reflux Burden, Even in Children That Aspirate, Does Not Increase Pediatric Hospitalization. Abstract

  28. TGFßR1 inhibition blocks the formation of stenosis in tissue-engineered vascular grafts. J Am Coll Cardiol. 2015 Feb 10; 65(5):512-4. View TGFßR1 inhibition blocks the formation of stenosis in tissue-engineered vascular grafts. Abstract

  29. Was that last colonoscopy really negative? A surprising cause of rectal bleeding in a 75-year-old man. Gastroenterology. 2012 May; 142(5):e3-4. View Was that last colonoscopy really negative? A surprising cause of rectal bleeding in a 75-year-old man. Abstract

  30. Evaluation of the use of an induced puripotent stem cell sheet for the construction of tissue-engineered vascular grafts. J Thorac Cardiovasc Surg. 2012 Mar; 143(3):696-703. View Evaluation of the use of an induced puripotent stem cell sheet for the construction of tissue-engineered vascular grafts. Abstract

  31. Challenges in translating vascular tissue engineering to the pediatric clinic. Vasc Cell. 2011 Oct 14; 3(1):23. View Challenges in translating vascular tissue engineering to the pediatric clinic. Abstract

  32. Characterization of the natural history of extracellular matrix production in tissue-engineered vascular grafts during neovessel formation. Cells Tissues Organs. 2012; 195(1-2):60-72. View Characterization of the natural history of extracellular matrix production in tissue-engineered vascular grafts during neovessel formation. Abstract

  33. A critical role for macrophages in neovessel formation and the development of stenosis in tissue-engineered vascular grafts. FASEB J. 2011 Dec; 25(12):4253-63. View A critical role for macrophages in neovessel formation and the development of stenosis in tissue-engineered vascular grafts. Abstract

  34. Determining the fate of seeded cells in venous tissue-engineered vascular grafts using serial MRI. FASEB J. 2011 Dec; 25(12):4150-61. View Determining the fate of seeded cells in venous tissue-engineered vascular grafts using serial MRI. Abstract

  35. Tissue-engineered vascular grafts form neovessels that arise from regeneration of the adjacent blood vessel. FASEB J. 2011 Aug; 25(8):2731-9. View Tissue-engineered vascular grafts form neovessels that arise from regeneration of the adjacent blood vessel. Abstract

  36. Cell-seeding techniques in vascular tissue engineering. Tissue Eng Part B Rev. 2010 Jun; 16(3):341-50. View Cell-seeding techniques in vascular tissue engineering. Abstract

  37. A novel mutation in two families with limb-girdle muscular dystrophy type 2C. Neurology. 2006 Jul 11; 67(1):167-9. View A novel mutation in two families with limb-girdle muscular dystrophy type 2C. Abstract

BESbswy